Cargando…

Correction to: Role of Bruton’s tyrosine kinase in B cells and malignancies

Detalles Bibliográficos
Autores principales:	Pal Singh, Simar, Dammeijer, Floris, Hendriks, Rudi W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446284/ https://www.ncbi.nlm.nih.gov/pubmed/30943993 http://dx.doi.org/10.1186/s12943-019-1009-z

Ejemplares similares

Role of Bruton’s tyrosine kinase in B cells and malignancies
por: Pal Singh, Simar, et al.
Publicado: (2018)

Correction to: Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features
por: Shirley, Matt
Publicado: (2021)

Role of Bruton's Tyrosine Kinase in B Cell Development
por: Maas, Alex, et al.
Publicado: (2001)

Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B‐cell receptor signaling in mice
por: Rip, Jasper, et al.
Publicado: (2021)

Distinct Roles for Bruton's Tyrosine Kinase in B Cell Immune Synapse Formation
por: Roman-Garcia, Sara, et al.
Publicado: (2018)

Targeting Bruton’s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies
por: Neys, Stefan F. H., et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease
por: Neys, Stefan F. H., et al.
Publicado: (2021)

A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies
por: Moore, Donald C., et al.
Publicado: (2021)

Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features
por: Shirley, Matt
Publicado: (2021)

Evidence for enhanced Bruton’s tyrosine kinase activity in transitional and naïve B cells of patients with granulomatosis with polyangiitis
por: von Borstel, Anouk, et al.
Publicado: (2019)

Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies
por: Gu, Danling, et al.
Publicado: (2021)

Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies
por: Abbas, Hussein A., et al.
Publicado: (2021)

Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies
por: Song, Yuqin, et al.
Publicado: (2023)

Bruton's Tyrosine Kinase Is Essential for Human B Cell Tolerance
por: Ng, Yen-Shing, et al.
Publicado: (2004)

Enhanced Bruton’s tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis
por: Heukels, Peter, et al.
Publicado: (2019)

Bruton's Tyrosine Kinase in Neutrophils Is Crucial for Host Defense against Klebsiella pneumoniae
por: Liu, Zhe, et al.
Publicado: (2022)

Bruton's tyrosine kinase: oncotarget in myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2012)

Editorial: Targeting Bruton Tyrosine Kinase
por: Brunner, Cornelia, et al.
Publicado: (2022)

Targeting Bruton’s Tyrosine Kinase in CLL
por: Ahn, Inhye E., et al.
Publicado: (2021)

Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies
por: Campbell, Robert, et al.
Publicado: (2018)

Structural Complementarity of Bruton’s Tyrosine Kinase and Its Inhibitors for Implication in B-Cell Malignancies and Autoimmune Diseases
por: Najmi, Asim, et al.
Publicado: (2023)

Bruton's Tyrosine Kinase Cooperates with the B Cell Linker Protein SLP-65 as a Tumor Suppressor in Pre-B Cells
por: Kersseboom, Rogier, et al.
Publicado: (2003)

Role of Bruton’s Tyrosine Kinase in Stage III Colorectal Cancer
por: Basile, Debora, et al.
Publicado: (2019)

Bruton's Tyrosine Kinase Regulates the Activation of Gene Rearrangements at the λ Light Chain Locus in Precursor B Cells in the Mouse
por: Dingjan, Gemma M., et al.
Publicado: (2001)

Regulatory Phosphorylation of Ikaros by Bruton's Tyrosine Kinase
por: Ma, Hong, et al.
Publicado: (2013)

Second-generation inhibitors of Bruton tyrosine kinase
por: Wu, Jingjing, et al.
Publicado: (2016)

Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma
por: Von Suskil, Max, et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase and Its Isoforms in Cancer
por: Wang, Xianhui, et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase Inhibition in Multiple Sclerosis
por: Schneider, Raphael, et al.
Publicado: (2022)

Bruton tyrosine kinase inhibitors for multiple sclerosis
por: Krämer, Julia, et al.
Publicado: (2023)

Bruton’s tyrosine kinase is at the crossroads of metabolic adaptation in primary malignant human lymphocytes
por: Sharif-Askari, Bahram, et al.
Publicado: (2019)

Mediation of transitional B cell maturation in the absence of functional Bruton’s tyrosine kinase
por: Tanwar, Shalini, et al.
Publicado: (2017)

Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect
por: Wang, Haoran, et al.
Publicado: (2022)

Correction: Bruton's Agammaglobulinemia and COVID-19
por: Hovey, Justin G, et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase-Mediated Signaling in Myeloid Cells Is Required for Protective Innate Immunity During Pneumococcal Pneumonia
por: de Porto, Alexander P., et al.
Publicado: (2021)

The evolving role of Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia
por: Gordon, Max J., et al.
Publicado: (2021)

Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus
por: Patsatsi, Aikaterini, et al.
Publicado: (2021)

Translational autoimmunity in pemphigus and the role of novel Bruton tyrosine kinase inhibitors
por: Naik, Piyu Parth
Publicado: (2022)

Structural mechanism for Bruton’s tyrosine kinase activation at the cell membrane
por: Wang, Qi, et al.
Publicado: (2019)

Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells
por: Bam, R, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ijqpeps71vp9i17hr7h1dlhfha